This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Max H. Weil, MD, PhD, MACP

Arch Intern Med. 1994;154(11):1183-1184.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

IN AN EARLIER comment on the landmark article by Ziegler and coworkers¹ on the treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibodies, our group² expressed discomfort with their recommendation that these antibodies to endotoxin be administered routinely. It was then apparent that successful treatment with this anti—lipid A antibody was contingent on the clinician's capability to make an early diagnosis of bacteremia and to further establish that the bacteremia was caused by endotoxin-producing enteric bacilli. Otherwise, the majority of patients would be exposed to potential risks without likelihood of benefit and with alarmingly high monetary costs. Subsequent articles reaffirmed these conclusions and the Food and Drug Administration disapproved HA-1A antibody for routine clinical use in the United States. Unfortunately, trials of the murine anti—endotoxin antibody, E5, were also disappointing, as were the trials on inhibitors of nonspecific mediators with antibodies to tumor necrosis factor . . . [Full Text PDF of this Article]

Author Affiliations
Institute of Critical Care Medicine FUHS/The Chicago Medical School 3333 Green Bay Rd North Chicago, IL 60064

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?